相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Costimulation Blockade Alters Germinal Center Responses and Prevents Antibody-Mediated Rejection
E. J. Kim et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
A Systematic Review of Conversion From Calcineurin Inhibitor to Mammalian Target of Rapamycin Inhibitors for Maintenance Immunosuppression in Kidney Transplant Recipients
W. H. Lim et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival
Jean-Emmanuel Serre et al.
KIDNEY INTERNATIONAL (2014)
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial
Richard Haynes et al.
LANCET (2014)
Long-Term Exposure to Belatacept in Recipients of Extended Criteria Donor Kidneys
B. Charpentier et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Long-Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long-Term Extension of the BENEFIT Study
L. Rostaing et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Two-Year Randomized Controlled Prospective Trial Converting Treatment of Stable Renal Transplant Recipients With Cutaneous Invasive Squamous Cell Carcinomas to Sirolimus
Judith M. Hoogendijk-van den Akker et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Antibody-mediated vascular rejection of kidney allografts: a population-based study
Carmen Lefaucheur et al.
LANCET (2013)
Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades
David Michonneau et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2013)
Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation
Diane Cibrik et al.
TRANSPLANTATION (2013)
Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients
F. Vincenti et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys
J. O. M. Pestana et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer
S. B. Campbell et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Five-Year Results of a Randomized Trial Comparing De Novo Sirolimus and Cyclosporine in Renal Transplantation: The Spiesser Study
Y. Lebranchu et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus with Cyclosporine After Kidney Transplantation
L. Liefeldt et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation
L. Mjornstedt et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Belatacept and Tregs: friends or foes?
Nina Pilat et al.
IMMUNOTHERAPY (2012)
Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation
Sylvie Euvrard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation
Robert M. Langer et al.
TRANSPLANT INTERNATIONAL (2012)
Switching from Calcineurin Inhibitor-based Regimens to a Belatacept-based Regimen in Renal Transplant Recipients: A Randomized Phase II Study
Lionel Rostaing et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Meta-Analysis of Calcineurin-Inhibitor-Sparing Regimens in Kidney Transplantation
Adnan Sharif et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
Klemens Budde et al.
LANCET (2011)
Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials
Liset H. M. Pengel et al.
TRANSPLANT INTERNATIONAL (2011)
A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study)
A. Durrbach et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)
F. Vincenti et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Five-Year Safety and Efficacy of Belatacept in Renal Transplantation
Flavio Vincenti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses
Geertrude H. Struijk et al.
KIDNEY INTERNATIONAL (2010)
Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study
Henrik Ekberg et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Thymoglobulin Induction and Sirolimus Versus Tacrolimus in Kidney Transplant Recipients Receiving Mycophenolate Mofetil and Steroids
Denis Glotz et al.
TRANSPLANTATION (2010)
Long-TermImpact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENCE Study 3-Year Follow Up
L. Frimat et al.
JOURNAL OF TRANSPLANTATION (2010)
Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study
Y. Lebranchu et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Everolimus With Very Low-Exposure Cyclosporine A in De Novo Kidney Transplantation: A Multicenter, Randomized, Controlled Trial
Maurizio Salvadori et al.
TRANSPLANTATION (2009)
The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation
J. A. Bluestone et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness
Laurence Chan et al.
TRANSPLANTATION (2008)
Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor
Antoine Durrbach et al.
TRANSPLANTATION (2008)
Effects of Immunosuppressive Drugs On Purified Human B Cells: Evidence Supporting the Use of MMF and Rapamycin
Sebastiaan Heidt et al.
TRANSPLANTATION (2008)
Reduced exposure to calcineurin inhibitors in renal transplantation
Henrik Ekberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression
Domingo Hernandez et al.
TRANSPLANTATION (2007)
Germinal-center organization and cellular dynamics
Christopher D. C. Allen et al.
IMMUNITY (2007)
Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR study
H. Ekberg et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients
Helio Tedesco-Silva et al.
TRANSPLANT INTERNATIONAL (2007)
Impact of cyclosporine reduction with MMF:: A randomized trial in chronic allograft dysfunction.: The 'reference' study
L. Frimat et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial
Marc Hazzan et al.
TRANSPLANTATION (2006)
Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients
Anders Asberg et al.
TRANSPLANTATION (2006)
Messenger RNA for FOXP3 in the urine of renal-allograft recipients
T Muthukumar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients
S Vítko et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring
G Ciancio et al.
TRANSPLANTATION (2005)
Costimulation blockade with belatacept in renal transplantation
F Vincenti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil:: Results from a prospective, randomized trial
M Hazzan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Everolimus versus mycophenolate mofetil in the prevention of rejection in de Novo renal transplant recipients: A 3-year randomized, multicenter, phase III study
MI Lorber et al.
TRANSPLANTATION (2005)
Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study
D Abramowicz et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the creeping creatinine study
C Dudley et al.
TRANSPLANTATION (2005)
Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies
S Vitko et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy
B Suwelack et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Anti-CD40 therapy extends renal allograft survival in rhesus macaques
TC Pearson et al.
TRANSPLANTATION (2002)
Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
H Kreis et al.
TRANSPLANTATION (2000)
分享论文
